EUVIMEDEUVIMED entdecken
Open Access

Network analysis of FDA approved drugs and their targets

Avi Ma'ayan, Sherry L Jenkins, Joseph Goldfarb, Ravi Iyengar

Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine · 2007

DOI: 10.1002/msj.20002 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine, 2007. Verfasst von Avi Ma'ayan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Systems Therapeutics, Mount Sinai School of Medicine, New York, New York 10029, USA. Hauptthemen laut MEDLINE: Computational Biology, Databases, Factual, Drug Approval, United States Food and Drug Administration. Die Arbeit wurde bisher 96-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The global relationship between drugs that are approved for therapeutic use and the human genome is not known. We employed graph‐theory methods to analyze the Federal Food and Drug Administration (FDA) approved drugs and their known molecular targets. We used the FDA Approved Drug Products with Therapeutic Equivalence Evaluations 26 th Edition Electronic Orange Book (EOB) to identify all FDA approved drugs and their active ingredients. We then connected the list of active ingredients extracted from the EOB to those known human protein targets included in the DrugBank database and constructed a bipartite network. We computed network statistics and conducted Gene Ontology analysis on the drug targets and drug categories. We find that drug to drug‐target relationship in the bipartite network is scale‐free. Several classes of proteins in the human genome appear to be better targets for drugs since they appear to be selectively enriched as drug targets for the currently FDA approved drugs. These initial observations allow for development of an integrated research methodology to identify general principles of the drug discovery process. Mt Sinai J Med 74:27–32, 2007. © 2007 Mount Sinai School of Medicine

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Computational BiologyDatabases, FactualDrug ApprovalUnited States Food and Drug AdministrationHumansSystems BiologyUnited States

Autor:innen und Institutionen

  • Department of Pharmacology and Systems Therapeutics, Mount Sinai School of Medicine, New York, New York 10029, USA.

Förderung

  • NIGMS NIH HHS

Zitieren

APA

Ma'ayan, A., Jenkins, S. L., Goldfarb, J., & Iyengar, R. (2007). Network analysis of FDA approved drugs and their targets. Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine. https://doi.org/10.1002/msj.20002

Vancouver

Ma'ayan A, Jenkins SL, Goldfarb J, Iyengar R. Network analysis of FDA approved drugs and their targets. Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine. 2007. doi:10.1002/msj.20002

BibTeX
@article{Maayan2007,
  author = {Ma'ayan, Avi and Jenkins, Sherry L and Goldfarb, Joseph and Iyengar, Ravi},
  title = {Network analysis of FDA approved drugs and their targets},
  journal = {Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine},
  year = {2007},
  doi = {10.1002/msj.20002}
}
Kostenlos starten →